Delivery: Off-The-Shelf Antibodies Steer CRISPR-Cas Particles to Target Cells

A Stanford-led team has built virus-like particles that take their targeting instructions from ordinary commercial antibodies, clipped on in half an hour rather than engineered into the envelope. Used as a screening tool, the system identified CD56 as a workable entry point for editing neural progenitor cells in the fetal mouse brain.

By: Gorm Palmgren - Oct. 21, 2026
News
Interested in hosting a webinar on CMN?

Contact us to learn more about our CMN Webinars package.

+35k readers | +35k followers | Top-1 CRISPR News Site | sales@crisprmedicinenews.com | Webinars

Cell-type-specific delivery remains the limiting step in therapeutic genome editing, and enveloped vectors usually hard-code their tropism by fusing antibody fragments, nanobodies or viral fusogens into the particle surface – a slow cycle restricted to the few binders already available. The novel designer antibody-routed nanoparticles (DARTs) instead display a generic capture moiety – either an anti-FITC single-chain fragment or monomeric streptavidin – while a binding-deficient VSV-G variant mediates endosomal escape. Thirty minutes of incubation with a commercial FITC-conjugated or biotinylated antibody is enough to set their targeting.

HIV-1-derived DARTs delivered SpCas9-sgRNA ribonucleoproteins, and optimisation of Cas9 loading, the protease linker and nuclear-localisation signals increased potency without appreciable antibody-independent editing in suspension cells.

Using single antibodies or combinations, the researchers targeted T-cell subsets, fibroblasts and human iPSC-derived neural progenitors; CD56- or CD133-directed particles produced up to 60% B2M knockout in the latter. The interface also worked with MMLV particles carrying Cas9 or an adenine base editor and with integrative lentivirus.

For the in vivo test, CD56-programmed DARTs were injected intracerebroventricularly into E15.5 Ai9 mouse foetuses. Four days later, selected ventricle-adjacent regions in one analysed brain section showed 83–93% target-cell specificity and editing in 11–16% of Sox2-positive cells.

The authors position DART as a discovery tool rather than a therapeutic vector, since free antibody shed in vivo would be expected to add to the immunogenicity of the particles themselves; once an antigen is validated, the targeter can be rebuilt as a membrane-integrated binder.

The study was led by Goldie Roth and senior authors Aijun Wang and Lei S. Qi at Stanford University and the University of California, Davis. It was posted as a bioRxiv preprint on 20 October 2026.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNewsHashtagStickyHashtagCMN BriefsHashtagDeliveryHashtagIn vivoHashtagRibonucleoprotein (RNP)HashtagVirus-like particle (VLP)HashtagCas9

close
Search CRISPR Medicine